Search
Twitter-square Facebook-square Linkedin Youtube

About Us

We’re on a mission to make cancer more detectable.

Our mission is to provide medical professionals the tools
to make better, more informed decisions for better patient outcomes.

Early detection saves lives

Imagion is the 1st-mover expanding biomedical access and application impact of SPIONS (superparamagnetic iron oxide nanoparticles).

By combining high-sensitivity imaging technologies with our innovative biomedically safe nanoparticles, MagSense® technology, we aim to improve clinicians’ ability to visualize tumors and metastases with standard MRI instruments.

Our MagSense® technology
Meet the leadership team
Contact Imagion Biosystems

aNANOtation
WHAT ARE SPIONS?

Superparamagnetic iron oxide nanoparticles (SPIONs) are tiny, biocompatible particles that exert a local magnetic force in response to the pulsed magnetic field of the MRI, making them ideal for non-invasive detection with standard diagnostic imaging. They can be used for diagnostics, therapy, and tracking of cells within the body, offering a versatile and promising tool in biomedicine.

Get involved with our proprietary nanoparticles

magfi glass icon_460x460

Diagnostic Imaging

MagSense® imaging agents can be developed for many types of solid tumors and can be used at multiple stages of diagnosis including primary diagnosis, staging, and prognosis of diseases.
About MagSense®

Other Biomedical Applications

We supply nanoparticles that can be used in third-party branded products across hyperthermia, human and animal vaccines, and cancer screening and treatments.

Partner with us
About Imagion Biosystems

Purchase SPIONS

We sell our superparamagnetic iron oxide PrecisionMRX® nanoparticles to institutions for research purposes.

Multiple coatings types are available.

Shop nanoparticles

Why you should use our PrecisionMRX® magnetic nanoparticles for your biomedical applications

We have developed proprietary methods for making magnetic nanoparticles that enable precise control of key attributes, such as size, size-dispersity, and magnetic properties, that are differentiating for many biomedical applications.
Learn more about PrecisionMRX®

Meet our team of Imagioneers

Geoff Hollis
CFO & Company Secretary
Marie Zhang, PhD
VP Research & Preclinical Development
Elana Levin
Director of Quality Assurance
Carmen Solkowski
Director of Operations
Mee Wa Wong, PhD
Director of Product Market Development
Sormeh Mahjouri
Program Director
Koushik Govindarajan
Clinical Scientist
Nitika Neha
Clinical Trial Manager
Eric Smith-Nguyen
Sr. Research Associate
Hannah Campbell
Senior Accountant
Casie Ost
Marketing Communications Manager
Michael Shun
Nanoparticle Production Tech
Kevin Forero
Nanoparticle Production Tech

Recent Milestones

December 2023

Imagion was selected to present in a Poster Spotlight Discussion at San Antonio Breast Cancer Symposium; MagSense® HER2 Imaging Agent: Molecular MRI for the Detection of Axillary Nodal Metastasis in Subjects with HER2+ Breast Cancer.  More >

December 2023

October 2023

Imagion announces progress with MagSense® Folate Receptor program in multiple translatable animal models of Ovarian Cancer at AACR’s Special Conference on Ovarian Cancer.  More >

October 2023

August 2023

Imagion signs MOU with Prestige Biopharma to develop early pancreatic cancer diagnostic test.  More >

August 2023

July 2023

Closed enrollment for Phase 1 of the MagSense® HER2 Imaging Agent (MSH2IA) study.

July 2023

June 2023

Expands collaboration with Siemens Healthineers Pty Ltd. of Australia and agree to collaborate in the US in anticipation of undertaking the Phase 2 study for MagSense® HER2 imaging agent.  More >

June 2023

March 2023

The Phase 1 data and independent expert review support IBX continued development of the MagSense® nanoparticle technology for molecular MRI of cancer. More >

March 2023

Feb 2023

Updated strategy to develop the MagSense® nanoparticle technology for use with clinical MRI systems.

Feb 2023

Feb 2023

Independent review by radiologists confirmed the MagSense® HER2 Imaging Agent produces a unique and differentiable image contrast in lymph nodes suspicious for tumor. This unique molecular signature is critical to discriminate lymph nodes with tumor cells from normal nodes and has the potential to improve nodal assessment for staging over current methods.

Feb 2023

Dec 2022

Presented interim data from MagSense® HER2 Breast Cancer Phase I study at the San Antonio Breast Cancer Symposium showing imaging agent showed no safety findings of significance and reaches its target tissue (axillary lymph nodes) with the planned route of administration and shows unique and differentiable MR contrast pattern in nodes suspicious for tumor.

Dec 2022

Sept 2022

Presented prostate cancer research data at the World Molecular Imaging Congress with MagSense® imaging agent showing high specificity and selectivity

Sept 2022

Apr 2022

Sponsored Research Agreement executed with researchers at Massachusetts General Hospital focuses on MRI 

Apr 2022

Mar 2022

MagSense® HER2 Breast Cancer Phase I study interim results indicate imaging agent is well-tolerated and is reaching patient’s lymph nodes

Mar 2022

Aug 2021

Joint Development Agreement with Global Cancer Technologies to develop nanocrystals for treatment of breast cancer

Aug 2021

May 2021

Collaboration with Patrys (ASX:PAB) for Brain Cancer imaging

May 2021

May 2021

First patient dosed in Phase I study

May 2021

Mar 2021

Receive CSIRO grant to support Prostate Cancer imaging research

Mar 2021

Mar 2020

MagSense® HER2 Breast Cancer Phase I study opens for enrolment

Mar 2020

Oct 2020

HREC approval for MagSense® HER2 Breast Cancer Phase I study in Australia

Oct 2020

May 2020

Research collaboration with Siemens

May 2020

Jul 2019

Received FDA designation as a ”Breakthrough Device”

Jul 2019

Drive a discovery & development engine

Approaching MagSense® Partnerships

Imagion Biosystems is actively seeking strategic partners to accelerate the development of our nanoparticles by leveraging the unique capabilities of each company.

MagSense® products are disruptive – enabling molecular MRI:

      • Primary diagnosis
      • Primary staging & treatment planning
      • Companion diagnostics
Learn more about partnerships

World class scientific collaborations & partnerships

“Since working with Imagion Biosystems for the last few years, we’ve been able to incorporate their iron oxide nanoparticles into our hyperthermia therapeutic platform. The consistent high quality of the iron oxide nanoparticles has allowed us to ramp up our preclinical testing and move us towards human clinical trials."
Ofer Shalev
Ofer ShalevCEO, New Phase

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Get in touch

About Imagion Biosystems

Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.

Contact us

  • info@imagionbio.com
  • Imagion Biosystems, Ltd. Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000, Australia
  • AU +61 3 9692 7222
  • Imagion Biosystems, Inc. PO Box 4410 Incline Village, NV 89450 United States

Join our email list

Stay informed about our latest news and developments.

© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance

Twitter-square Facebook-square Linkedin Youtube